tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Cardio Diagnostics, AGEPHA Pharma in deal for heart disease study

Cardio Diagnostics (CDIO) Holdings and AGEPHA Pharma announced an agreement that will enable the validation of a precision-guided approach to treating inflammation-driven coronary heart disease. AGEPHA Pharma will supply its FDA-approved anti-inflammatory medication, LODOCO, for a Cardio Diagnostics-sponsored clinical study. The study will explore the use of Cardio Diagnostics’ PrecisionCHD test to identify patients with inflammation-driven CHD and assess their response to LODOCO.

Elevate Your Investing Strategy:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1